Thalidomide--cost and development

Comment

Peter C Amadio. Mayo Clin Proc. 2005 Jan.

. 2005 Jan;80(1):134; author reply 134-6.

doi: 10.1016/S0025-6196(11)62970-4.

No abstract available

Comment on

Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.
Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Kyle RA, et al. Mayo Clin Proc. 2004 Jul;79(7):859-66. doi: 10.4065/79.7.859. Mayo Clin Proc. 2004. PMID: 15244381
Clinical course of patients with relapsed multiple myeloma.
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Witzig TE, Lust JA, Larson DR, Kyle RA, Greipp PR. Kumar SK, et al. Mayo Clin Proc. 2004 Jul;79(7):867-74. doi: 10.4065/79.7.867. Mayo Clin Proc. 2004. PMID: 15244382
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K. Richardson P, et al. Mayo Clin Proc. 2004 Jul;79(7):875-82. doi: 10.4065/79.7.875. Mayo Clin Proc. 2004. PMID: 15244383 Clinical Trial.